Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions
International Journal of Molecular Sciences · 07.10.2024 · 25 (19) · 10765
DOI: 10.3390/ijms251910765 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.10.2024. Verfasst von Silvia Mara Baez Rodriguez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania. Hauptthemen laut MEDLINE: Glioblastoma, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma is known to be one of the most aggressive and fatal human cancers, with a poor prognosis and resistance to standard treatments. In the last few years, many solid tumor treatments have been revolutionized with the help of immunotherapy. However, this type of treatment has failed to improve the results in glioblastoma patients. Effective immunotherapeutic strategies may be developed after understanding how glioblastoma achieves tumor-mediated immune suppression in both local and systemic landscapes. Biomarkers may help identify patients most likely to benefit from this type of treatment. In this review, we discuss the use of immunotherapy in glioblastoma, with an emphasis on immune checkpoint inhibitors and the factors that influence clinical response. A Pubmed data search was performed for all existing information regarding immune checkpoint inhibitors used for the treatment of glioblastoma. All data evaluating the ongoing clinical trials involving the use of ICIs either as monotherapy or in combination with other drugs was compiled and analyzed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania.
- Neurosurgical Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania.
- Medical Department, University of Medicine and Pharmacy "G. T. Popa", 700115 Iasi, Romania.
- Biochemistry Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania.
ORCID-Profile: Ligia Gabriela Tataranu, Amira Kamel, Serban Turliuc, Radu Eugen Rizea, Anica Dricu
Zitieren
APA
Rodriguez, S. M. B., Tataranu, L. G., Kamel, A., Turliuc, S., Rizea, R. E., & Dricu, A. (2024). Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions. International Journal of Molecular Sciences, 25(19), 10765. https://doi.org/10.3390/ijms251910765
Vancouver
Rodriguez SMB, Tataranu LG, Kamel A, Turliuc S, Rizea RE, Dricu A. Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions. International Journal of Molecular Sciences. 2024;25(19):10765. doi:10.3390/ijms251910765
BibTeX
@article{Rodriguez2024,
author = {Rodriguez, Silvia Mara Baez and Tataranu, Ligia Gabriela and Kamel, Amira and Turliuc, Serban and Rizea, Radu Eugen and Dricu, Anica},
title = {Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {19},
pages = {10765},
doi = {10.3390/ijms251910765}
}
EUVIMED